FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
6 trends tracked about this subject — the full history, oldest to newest below.
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
The FDA is requiring all GLP-1 drug makers to add a warning about NAION, a rare eye condition that can cause sudden blindness, to their prescribing information.
A growing wave of coverage examines newly reported links between popular GLP-1 medications and rare instances of severe vision loss.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent studies and new lawsuits connect popular GLP-1 medications to potential risks of sudden vision loss and eye disease.
A Georgia woman has joined a growing lawsuit connecting popular GLP-1 weight loss drugs to a rare and blinding eye condition.